Report Categories
View AllRecent Articles
View All
Genprex GNPX EPS beats by 38 yet shares decline 284 as revenue questions linger
STOK Stoke Therapeutics posts wider than expected Q4 2025 loss shares gain slightly despite steep earnings miss
Morgan Stanley MS Adjusts KeyCorp KEY Price Target Amid Shifting Regional Bank Narrative
EMN Eastman posts 17 percent Q1 2026 EPS beat yet shares drop 201 percent in todays trading